S.C.R. NO. 86

MAR 1 0 2023

## SENATE CONCURRENT RESOLUTION

RECOGNIZING AND SUPPORTING ONGOING COLLABORATIVE EFFORTS TO IMPLEMENT A STATEWIDE STRATEGY TO ELIMINATE VIRAL HEPATITIS TYPES A, B, AND C IN HAWAII.

WHEREAS, viral hepatitis is an inflammation of the liver 1 caused by a preventable, treatable viral infection; and 2 3 4 WHEREAS, the most common forms of viral hepatitis in the United States are hepatitis types A, B, and C; and 5 6 7 WHEREAS, viral hepatitis types B and C have been linked to 8 cirrhosis and liver cancer, diseases that affect Hawaii residents at disproportionately high rates; and 9 10 WHEREAS, the State's hepatitis B mortality rate is higher 11 than that of the nationwide average and was nearly triple the 12 nationwide average in 2019; and 13 14 WHEREAS, the life expectancy for Hawaii residents living 15 with hepatitis C is twenty years less than that of residents 16 living without hepatitis C; and 17 18 WHEREAS, certain communities are at higher risk for 19 developing viral hepatitis, including indigenous, Asian American 20 and Pacific Islander, incarcerated, veteran, homeless, pregnant, 21 and LGBTQ+ communities; and 22 23 24 WHEREAS, the State is engaged in proactive measures to help 25 eliminate viral hepatitis in underserved and at-risk communities by expanding Med-QUEST to cover hepatitis C medications; 26 27 offering syringe service programs to reduce the spread of hepatitis C among people who inject drugs; identifying and 28 29 supporting foreign-born women and families at high risk of contracting hepatitis B; and ensuring that homeless communities 30 are immunized against hepatitis A; and 31 32



## S.C.R. NO. 86

WHEREAS, state agencies and private organizations are also 1 helping to reduce and eliminate viral hepatitis types A, B, and 2 C by offering vaccines, testing, education, training programs, 3 and care services; and 4 5 WHEREAS, on July 28, 2020, Hep Free Hawaii, a coalition 6 dedicated to increasing viral hepatitis awareness, issued "Hep 7 Free 2030: The Hawaii Hepatitis Elimination Strategy 2020-2030" 8 9 (Hep Free 2030), a ten-year statewide strategy to help eliminate viral hepatitis types A, B, and C in Hawaii; and 10 11 12 WHEREAS, Hep Free 2030 identifies awareness and education, access to services, advocacy at all levels, equity, and data 13 driven decision-making as priorities to eliminating viral 14 15 hepatitis in Hawaii by 2030; and 16 WHEREAS, continued coordination and ongoing efforts are 17 needed to further implement Hep Free 2030; now, therefore, 18 19 20 BE IT RESOLVED by the Senate of the Thirty-second Legislature of the State of Hawaii, Regular Session of 2023, the 21 House of Representatives concurring, that this body recognizes 22 23 and supports ongoing collaborative efforts by state agencies and private organizations to implement Hep Free 2030: The Hawaii 24 Hepatitis Elimination Strategy 2020-2030; and 25 26 27 BE IT FURTHER RESOLVED that the Senate and the House of Representatives acknowledge viral hepatitis to be a public 28 29 health priority of the State; and 30 BE IT FURTHER RESOLVED that the Senate Standing Committee 31 on Health and Human Services and House Standing Committee on 32 Health and Homelessness are requested to convene a joint 33 informational briefing following the completion of the Regular 34 Session of 2023 and prior to the commencement of the Regular 35 Session of 2024 to assess the progress and status of 36 implementing Hep Free 2030 and determine any recommended future 37 legislative action; and 38 39 40 BE IT FURTHER RESOLVED that certified copies of this 41 Concurrent Resolution be transmitted to the President of the Senate, Speaker of the House of Representatives, Chair of the 42



S.C.R. NO. 86

Senate Standing Committee on Health and Human Services, Chair of
the House Standing Committee on Health and Homelessness, and Co Directors of Hep Free Hawaii.

- 4
- 5
- 6

34222 OFFERED BY;

